Financials in USD. Standardized financial statements.
A compact view of how Calliditas Therapeutics Ab turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Revenue? | $4,128 | $174,394 | $266,179 |
| Revenue Growth? | -97.6% | -34.5% | 0.0% |
| Cost of Revenue? | $273,091 | $271,653 | $300,604 |
| Gross Profit? | -$268,964 | -$97,258.5 | -$34,423.7 |
| Gross Margin? | -6515.6% | -55.8% | -12.9% |
| Operating Expenses? | $15.18M | $1.89M | $1.82M |
| Operating Income? | -$15.45M | -$1.99M | -$1.85M |
| EBITDA? | -$15.58M | -$1.71M | -$1.55M |
| Income Before Tax | -$14.84M | -$974,126 | -$1.86M |
| Income Tax Expense | $0 | $0 | $0 |
| Net Income? | -$14.84M | -$974,126 | -$1.86M |
| EPS? | $-0.57 | $-0.06 | $-0.12 |
| Diluted EPS? | $-0.57 | $-0.06 | $-0.12 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality